Key points are not available for this paper at this time.
expression (59% 16/27). This novel combination of venetoclax with bortezomib and dexamethasone has an acceptable safety profile and promising efficacy in patients with relapsed/refractory MM. This trial was registered at www.clinicaltrials.gov as #NCT01794507.
Moreau et al. (Tue,) studied this question.